Article Details

FDA Clock Starts for AstraZeneca and Merck in Prostate Cancer, Roche in DLBCL

Retrieved on: 2022-08-16 14:08:32

Tags for this article:

Click the tags to see associated articles and topics

FDA Clock Starts for AstraZeneca and Merck in Prostate Cancer, Roche in DLBCL. View article details on hiswai:

Excerpt

The FDA has accepted the sNDA for AstraZeneca and Merck's Lynparza and the sBLA for Genentech (Roche)'s for Polivy in diffuse large B-cell ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up